Major Depression Clinical Trial
Official title:
Exploring the Impact of Peripheral Immune Challenge on the "Triple Network" and "Dorsal Nexus" Functional Connectivity in Humans
Acquiring, processing and utilising "information" is crucial to any mental function
-including seemingly simple daily functions. Collectively called 'cognitive functions',
these processes are a result of different regions of the brain acting together.
Disruption of these cognitive functions increases the risk of development of mental health
problem. Recently it has been proposed that inflammatory pathways may contribute to
disorders of cognition and behaviour like depression.
This is largely due to research showing that those with inflammatory conditions like
arthritis are more likely to develop mental health problems like depression. Conversely,
those who suffer from mental health problems (even in the absence of inflammatory
conditions) have large amounts of inflammatory molecules in the blood. Studies in animals
suggest that inflammation outside the brain can reach and affect the brain in a number of
ways. So, does inflammation play a role in the development of cognitive and behavioural
symptoms? What are the pathways involved?
The current project tries to address this question. Specifically, the investigators intend
to use modern scanning techniques to examine the effect of inducing a low grade inflammation
(using a commonly used typhoid vaccine) to see how the inflammation affects how different
regions of the act together to perform cognitive functions.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
| Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
| Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
| Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
| Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
| Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
| Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
| Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
| Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
| Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
| Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
| Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
| Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
| Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
| Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
| Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
| Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
| Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
| Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
| Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 |